Reversal of the Marketing Authorizations for HPV Vaccines and Uncertainty Regarding Utilization in China
Biotechnology Law Report · 2018-08 · 37 (4) · 211-214
DOI: 10.1089/blr.2018.29081.nl ↗Kurz gefasst
Fachartikel in der Zeitschrift Biotechnology Law Report, 2018-08. Verfasst von Na Li und 1 weiteren Autor:innen. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 1 Literaturangaben.
Abstract (Originalsprache)
, by April 2018, the China Food and Drug Administration (CFDA) had quickly approved the marketing authorizations of a 9-valent HPV vaccine. This reversal in how long HPV vaccine approval in China took is gratifying, but there remain some issues and uncertainties in the use of the vaccines, which continue to negatively impact Chinese women’s health.
Zitieren
APA
Li, N., & Yu, X. (2018). Reversal of the Marketing Authorizations for HPV Vaccines and Uncertainty Regarding Utilization in China. Biotechnology Law Report, 37(4), 211-214. https://doi.org/10.1089/blr.2018.29081.nl
Vancouver
Li N, Yu X. Reversal of the Marketing Authorizations for HPV Vaccines and Uncertainty Regarding Utilization in China. Biotechnology Law Report. 2018;37(4):211-214. doi:10.1089/blr.2018.29081.nl
BibTeX
@article{Li2018,
author = {Li, Na and Yu, Xiang},
title = {Reversal of the Marketing Authorizations for HPV Vaccines and Uncertainty Regarding Utilization in China},
journal = {Biotechnology Law Report},
year = {2018},
volume = {37},
number = {4},
pages = {211--214},
doi = {10.1089/blr.2018.29081.nl}
}
EUVIMED